Veracyte (VCYT) CEO sells 45,523 shares under pre-set 10b5-1 plan

Rhea-AI Filing Summary

Veracyte, Inc. Chief Executive Officer Marc Stapley sold 45,523 shares of common stock on March 4, 2026 in two open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. The trades occurred at weighted average prices of $35.5553 and $36.2787 per share. Following these sales, he directly owns 357,554 Veracyte shares.

Insider Trade Summary

Net Seller: 45,523 shares ($1,637,594)

Net Sell 2 txns

Insider Stapley Marc

Role Chief Executive Officer

Sold 45,523 shs ($1.64M)

Type	Security	Shares	Price	Value
Sale	Common Stock	19,244	$35.5553	$684K
Sale	Common Stock	26,279	$36.2787	$953K

Holdings After Transaction: Common Stock — 383,833 shares (Direct)

Footnotes (1)

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025. Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $36.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $36.01 to $36.51. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stapley Marc

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		19,244	D	$35.5553(2)	383,833	D
Common Stock	03/04/2026		S(1)		26,279	D	$36.2787(3)	357,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $36.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. Represents weighted average sales price. Sale prices for the transactions range from $36.01 to $36.51. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veracyte (VCYT) CEO Marc Stapley report in this Form 4 filing?

Marc Stapley reported selling 45,523 shares of Veracyte common stock in open-market transactions. The sales took place on March 4, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025.

How many Veracyte (VCYT) shares did the CEO sell and at what prices?

The CEO sold 45,523 Veracyte common shares in two trades at weighted average prices of $35.5553 and $36.2787 per share. Footnotes state individual sale prices ranged from $35.00 to $36.51 across the reported transactions.

Does Marc Stapley still hold Veracyte (VCYT) shares after these sales?

Yes. After the reported transactions, Marc Stapley directly owns 357,554 shares of Veracyte common stock. This remaining ownership figure is disclosed in the Form 4 as the total number of shares held following the second reported sale.

Were the Veracyte (VCYT) CEO share sales part of a pre-set 10b5-1 plan?

Yes. A footnote explains these transactions were executed under a Rule 10b5-1 trading plan adopted by Marc Stapley on November 24, 2025. Such plans allow insiders to sell shares according to pre-established instructions.

On what date did the Veracyte (VCYT) CEO sell his shares?

All reported sales occurred on March 4, 2026. The Form 4 lists this single transaction date for both open-market sale entries, covering a combined total of 45,523 Veracyte common shares sold under the CEO’s Rule 10b5-1 plan.

What do the Form 4 footnotes say about the Veracyte (VCYT) sale prices?

The footnotes state the reported prices are weighted averages. Individual sale prices ranged from $35.00 to $36.00 for one group of trades and from $36.01 to $36.51 for the other, with detailed breakdowns available on request.